(CIDRAP News) A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.
The World Health Organization (WHO) reported 331 cases of swine influenza H1N1 in 11 countries as of 6 a.m. GMT today. The case numbers by country are United States, 109 (1 death) (these are yesterday's totals); Mexico, 156 (9 deaths), Canada, 34; Spain, 13; United Kingdom, 8; New Zealand, 3; Germany, 3; Israel, 2; and 1 each in Austria, the Netherlands, and Switzerland. [WHO update 7]
(CIDRAP News) A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culturea combination of techniques that entails some risk but may boost immune response and shorten production time.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.
(CIDRAP News) The H5N1 avian flu virus is continuing its relentless spread from bird to bird, with individual deaths in some countries marking new territory for the virus and massive die-offs and culling showing how quickly it can become entrenched.
The pathogen has been reported in wild birds in five new countriesAzerbaijan, Nigeria, Greece, Italy, and Bulgariain the past week. In addition, an H5 virus has been reported in Slovenia.